mCNV

Remibrutinib reduced relapse rates and improved disease progression rates

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica

The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

MS affects nearly three million people worldwide and has three main types

More than 186,000 men are diagnosed each year with mHSPC globally

Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates

This is the first and only at-home subcutaneous treatment option for this disease

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology